SciELO - Scientific Electronic Library Online

vol.37 issue6Ethical and methodological quality of non-interventional post-authorization studies promoted by hospital pharmacy departmentsAcquired haemophilia A in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin: role of rituximab author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Farmacia Hospitalaria

On-line version ISSN 2171-8695Print version ISSN 1130-6343


SANGRADOR PELLUZ, C.; MAIQUES LLACER, F. J.  and  SOLER COMPANY, E.. Safety in the clinical practica of the triple teraphy with telaprevir in chronic hepatitis C. Farm Hosp. [online]. 2013, vol.37, n.6, pp.489-493. ISSN 2171-8695.

Purpose: To study the safety of triple therapy with telaprevir and the time of appearance of the RAM in the treatment of hepatitis C. Method: A retrospective observational study (January 2012-June 2013) of patients with HCV genotype 1 who had completed 12 weeks of triple therapy with telaprevir. The following variables were needed to characterize patients, and those relating to the treatment received. The classification of ADR was performed according to criteria of the SIDA Division 1.0. Results: We included 88 patients (78% male), 75% cirrhotic patients. 40.9% were coinfected with HIV. The main ADR (incidence > 40%) including all grades: haematological toxicity, fatigue, hyperuricemia, hyperbilirubinemia and pruritus. Serious ADR (incidence > 15%): thrombocytopenia, anemia and neutropenia. 3.4% had severe toxicodermia. 51.1% required ribavirin dose adjustment, blood transfusions 13.6%, and 28.4% exogenous erythropoietin. The 8% required hospitalization motivated by treatment toxicity. The treatment was stopped for toxicity in 6.8% of patients: 3 severe toxicodermia, 2 severe haematological toxicity, and 1 severe emesis. Thrombocytopenia and hyperbilirubinemia occurred at an early stage in its higher degree of toxicity, while the other ADR presented progression longer periods. Conclusions: The study shows a superior toxicity profile to that described in clinical trials, mainly with regard to hematologic toxicity, and predicts a time range of highest probability of occurrence of ADR.

Keywords : Telaprevir; Safety; Triple therapy; Adverse drug reaction (ADR); Hepatitis C.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License